Drugs / LY3985297
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06395012 | Jun 2024 → Aug 2025 | — | Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY3985297 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06395012 ↗ |
| Route | Intravenous | “administered either intravenously (IV) or subcutaneously (SC).” NCT06395012 ↗ |
| Route | Subcutaneous | “administered either intravenously (IV) or subcutaneously (SC).” NCT06395012 ↗ |